Journal of the Egyptian National Cancer Institute

Scope & Guideline

Empowering oncology insights through open access.

Introduction

Welcome to the Journal of the Egyptian National Cancer Institute information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Journal of the Egyptian National Cancer Institute, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1110-0362
PublisherSPRINGER
Support Open AccessYes
CountryEgypt
TypeJournal
Convergefrom 2005 to 2009, from 2011 to 2024
AbbreviationJ EGYPT NATL CANCER / J. Egypt. Natl. Cancer Inst.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, NY 10004, UNITED STATES

Aims and Scopes

The Journal of the Egyptian National Cancer Institute focuses on disseminating high-quality research and clinical findings in the field of oncology. It aims to provide a platform for researchers and healthcare professionals to share innovative studies, clinical trials, and advancements in cancer treatment and diagnosis. The journal encompasses a wide array of topics that contribute to the understanding and management of cancer, reflecting both local and global health challenges.
  1. Clinical Oncology Research:
    The journal emphasizes clinical research, including trials and outcomes associated with various cancers, aiming to improve treatment protocols and patient care.
  2. Molecular and Cellular Oncology:
    A significant focus on the molecular mechanisms underlying cancer, including genetic and epigenetic studies, biomarker identification, and the role of microRNAs in tumorigenesis.
  3. Radiation and Surgical Oncology:
    Research on the effects and methodologies of radiation therapy and surgical interventions, including innovative techniques like deep inspiratory breath-hold in radiotherapy.
  4. Epidemiology and Public Health:
    Investigations into cancer epidemiology, including risk factors, prevention strategies, and the impact of socio-economic conditions on cancer incidence and outcomes.
  5. Translational Medicine:
    The journal supports studies that bridge laboratory research and clinical practice, highlighting advancements in personalized medicine and innovative therapeutic strategies.
In recent years, the Journal of the Egyptian National Cancer Institute has witnessed the emergence of several themes that reflect current trends in cancer research. These themes indicate a shift towards more innovative and patient-centered approaches in oncology.
  1. Precision Medicine and Biomarkers:
    There is an increasing focus on precision medicine, particularly the identification and validation of biomarkers for cancer diagnosis, prognosis, and treatment response, reflecting the personalized approach in oncology.
  2. Immunotherapy and Targeted Therapies:
    Research on immunotherapeutic strategies and targeted therapies has gained momentum, highlighting their efficacy and safety in various cancer types, as well as the exploration of combination therapies.
  3. Artificial Intelligence and Machine Learning in Oncology:
    The application of AI and machine learning techniques for cancer detection, diagnosis, and treatment planning is an emerging trend, showcasing the integration of technology in improving patient outcomes.
  4. Nutrition and Cancer Care:
    A growing interest in the role of nutrition and lifestyle factors in cancer prevention and survivorship has emerged, reflecting a holistic approach to cancer management.
  5. COVID-19 Impact on Cancer Care:
    The ongoing impact of the COVID-19 pandemic on cancer treatment and patient management has led to a surge in research addressing these challenges, emphasizing the need for adaptive strategies in oncology.

Declining or Waning

While the Journal of the Egyptian National Cancer Institute has a robust focus on various aspects of oncology, certain themes have shown a decline in prominence over recent years. This could be indicative of shifting research interests or advancements in specific areas that have led to reduced publication in older themes.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decrease in the publication of studies solely focused on traditional chemotherapy regimens, as the field shifts towards targeted therapies and immunotherapy.
  2. Basic Science without Clinical Application:
    Research that remains strictly within basic science without direct clinical relevance or application appears to be waning, as there is a greater emphasis on translational research.
  3. Case Reports of Rare Tumors:
    Though still valuable, the frequency of case reports on rare tumors has diminished, possibly reflecting a broader interest in larger cohort studies or systemic reviews that provide more generalizable data.
  4. Outdated Diagnostic Techniques:
    Studies focused on older diagnostic methods without incorporating the latest technological advancements, such as liquid biopsies or advanced imaging techniques, have become less frequent.

Similar Journals

South Asian Journal of Cancer

Championing open access to vital cancer research.
Publisher: GEORG THIEME VERLAG KGISSN: 2278-330XFrequency: 4 issues/year

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

Journal of Cancer

Unlocking the complexities of cancer together.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

BRITISH JOURNAL OF CANCER

Advancing Cancer Knowledge Through Rigorous Research.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

International Journal of Cancer Management

Driving collaboration in the fight against cancer.
Publisher: BRIEFLANDISSN: 2538-4422Frequency: 12 issues/year

The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

Gastric Cancer

Exploring Breakthroughs in Gastric Cancer Management.
Publisher: SPRINGERISSN: 1436-3291Frequency: 4 issues/year

Gastric Cancer is a leading journal in the field of oncology, published by SPRINGER in Japan. With an ISSN of 1436-3291 and an E-ISSN of 1436-3305, this esteemed journal aims to disseminate high-quality research focused on all aspects of gastric cancer, including its pathophysiology, diagnosis, treatment, and prevention. As an indicator of its academic excellence, Gastric Cancer is ranked in the top quartile (Q1) for Cancer Research, Gastroenterology, Medicine (miscellaneous), and Oncology categories as of 2023. The journal holds impressive Scopus rankings, being positioned #9 in Gastroenterology and #34 in Oncology, demonstrating its critical role in shaping advancements within these disciplines. Although not an open-access publication, it provides various access options for institutions and individuals looking to elevate their understanding of gastric cancer. With a converged publication history from 2000 to 2024, it serves as a vital resource for researchers, professionals, and students dedicated to eradicating this formidable disease.

HEMATOLOGICAL ONCOLOGY

Advancing the Frontiers of Hematological Research
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

Cancer Research Communications

Advancing the frontiers of cancer knowledge.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Advancing the Frontiers of Cancer Research
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0277-3732Frequency: 12 issues/year

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

CANCER GENE THERAPY

Unleashing the Power of Molecular Medicine in Oncology
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Oncology Research and Treatment

Empowering the future of oncology with cutting-edge insights.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.